SCHEMBL13035720

SCHEMBL13035720

Cc1nsc(N2CCC(C)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.46
TSHR P16473 4/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KDM4E B2RXH2 2/20 0.46
MAPK1 P28482 1/20 0.46
DPP4 P27487 5/20 0.43
TDP1 Q9NUW8 2/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
PKM P14618 1/20 0.37
GAA P10253 2/20 0.37
USP2 O75604 1/20 0.37
HTT P42858 1/20 0.37
MITF O75030 1/20 0.37
TP53 P04637 1/20 0.37
NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2273553 0.84 DPP4 (0.40) SMN1; SMN2TSHRALDH1A1HPGDNPC1
Hydrochloric Acid SCHEMBL2275641 0.82 DPP4 (0.40) SMN1; SMN2TSHRALDH1A1HPGDNPC1
SCHEMBL14308895 0.81 DPP4 (0.39) DPP4
SCHEMBL12988374 0.81 DPP4 (0.39) DPP4
SCHEMBL25261748 0.78 KDM4E (0.51) SMN1; SMN2TSHRALDH1A1HPGDNPC1
SCHEMBL14182484 0.78 DPP4 (0.40) DPP4KMT2A
SCHEMBL14182486 0.77 DPP4 (0.44) TSHRALDH1A1HPGDNPC1RAB9A
SCHEMBL13817550 0.77 DPP4 (0.43) SMN1; SMN2ALDH1A1HPGDNPC1RAB9A
SCHEMBL12454176 0.76 DPP4 (0.39) DPP4
SCHEMBL3150091 0.76 DPP4 (0.42) SMN1; SMN2KDM4EDPP4TDP1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858635-B2 Spiro compounds as modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-28 US disclosed
US-20080015179-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015179-A1 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 SMN1; SMN2 3349/4885TSHR 131/4885ALDH1A1 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.